Kyverna Therapeutics, Inc. (KYTX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Kyverna Therapeutics: Immune Reset Is Clinically Validated, Market Ignores Potential
Kyverna Therapeutics receives a strong buy rating with a $55 price target, driven by revolutionary Phase 2 data for KYV-101 in myasthenia gravis. KYV-101 demonstrated double the efficacy of standard care and enabled 100% of patients to achieve drug-free remission, with a best-in-class safety profile. The platform is significantly de-risked, with experienced management, strong financials, and clear near-term catalysts, including SPS BLA filing and a pivotal Phase 3 trial.
Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025
Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half of 2025. The global Myasthenia Gravis market is expected to generate sales of $6.7 billion by 2032. Release of topline data from phase 2 KYSA-8 study, using KYV-101 for the treatment of patients with Stiff Person Syndrome, expected in 1st half of 2026.
What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock
Kyverna Therapeutics, Inc. (KYTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Kyverna Therapeutics, Inc. (KYTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Kyverna Therapeutics, Inc. ever had a stock split?
Kyverna Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Warner Biddle CEO | NASDAQ (NGS) Exchange | 501976104 CUSIP |
| US Country | 112 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel cell therapies for patients suffering from autoimmune diseases. The company, originally known as BAIT Therapeutics, Inc., was rebranded to Kyverna Therapeutics in October 2019 and was established in 2018. Based in Emeryville, California, Kyverna is leveraging its expertise in cell therapy to address a range of autoimmune conditions. Through strategic partnerships and licensing agreements with industry leaders such as Intellia Therapeutics, Inc. and Kite, Kyverna is advancing its mission to transform the treatment landscape for autoimmune diseases. These collaborations are aimed at the research and development of innovative CAR T-cell therapy products for autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases.
Products and Services
- KYV-101
- KYV-201
- Further Product Development
An autologous CD19 CAR T-cell therapy, KYV-101 is at the forefront of Kyverna Therapeutics’ product pipeline. Designed to treat autoimmune diseases such as lupus nephritis and systemic sclerosis, KYV-101 is currently undergoing a Phase I clinical trial. Additionally, its therapeutic potential is being evaluated in Phase II clinical trials for myasthenia gravis and multiple sclerosis. By targeting CD19, a protein expressed on the surface of certain cells of the immune system, KYV-101 aims to offer a new therapeutic approach for patients with these debilitating conditions.
This allogeneic CD19 CAR T-cell product candidate represents Kyverna Therapeutics’ venture into off-the-shelf cell therapy solutions. KYV-201 is in the preclinical stage and targets multiple autoimmune diseases. The development of allogeneic CAR T-cell therapies like KYV-201 could significantly broaden the accessibility and reduce the time-to-treatment for patients, contrasting with the more personalized autologous CAR T-cell therapies that require cell customization for each patient.
In addition to KYV-101 and KYV-201, Kyverna Therapeutics is exploring the potential of CAR T-cell and other cell therapy approaches for a range of other autoimmune diseases, such as inflammatory bowel disease, which encompasses Crohn's disease and ulcerative colitis. These endeavors are part of Kyverna’s broader mission to discover and develop transformative treatments for autoimmune diseases, leveraging its platform and expertise in cell therapy to address unmet medical needs.
Contact Information
